Plain-English translation of NCT07170735 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Tuberculosis is a serious infection that affects millions of people worldwide, but diagnosing it can be slow and difficult—especially when the disease spreads beyond the lungs. This study is testing whether measuring tuberculosis DNA in blood and urine samples can help doctors diagnose the disease more quickly and accurately, and track how well treatment is working over time.
Current ways of diagnosing tuberculosis rely on sputum samples (which are hard to collect from children and elderly patients), invasive procedures like biopsies, or cultures that take weeks to show results. This trial exists because doctors need a faster, easier, non-invasive way to diagnose tuberculosis and monitor whether patients are getting better during treatment.
You likely qualify if…
You likely don't qualify if…
You would be placed into one of three groups: patients with active tuberculosis, patients with latent infection, or healthy controls. Your participation would involve giving blood and urine samples so researchers can measure tuberculosis DNA levels. The study will follow you over time to see whether these measurements help diagnose the disease and track treatment progress.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Hong Kong
Enrollment target
~85 participants
Started
February 2026
Primary completion
April 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ka Pang Chan, MBChB
Chinese University of Hong Kong
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.